This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Xichun Hu, Fudan University Identifier:
First received: July 27, 2012
Last updated: March 13, 2017
Last verified: January 2017
The addition of dimethyldiguanide might increase the efficacy of AI treatment in metastatic breast cancer.

Condition Intervention Phase
Metastatic Breast Cancer Drug: AI plus Dimethyldiguanide Drug: Aromatase Inhibitor Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.

Resource links provided by NLM:

Further study details as provided by Xichun Hu, Fudan University:

Primary Outcome Measures:
  • progression free survival [ Time Frame: 9 months ]

Estimated Enrollment: 60
Study Start Date: July 2012
Study Completion Date: July 2016
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: AI plus Dimethyldiguanide
AI 1 tablet qd plus Dimethyldiguanide 0.5 bid
Drug: AI plus Dimethyldiguanide
AI 1 tablet per day Dimethyldiguanide 0.5 bid
Other Names:
  • letrozole or exemestane
  • Dimethyldiguanide
Active Comparator: Aromatase Inhibitor
AI monotherapy
Drug: Aromatase Inhibitor
1 tablet per day
Other Name: letrozole or exemestane

Detailed Description:
The addition of dimethyldiguanide might increase the efficacy of AI in patients with metastatic breast cancer after the failure of the first line endocrine therapy.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • postmenopausal HR positive breast cancer patients;
  • inoperable locally advanced or metastatic breast cancer patients;
  • candidate for endocrine therapy;
  • ECOG equal to or less than 1;
  • adequate bone marrow function(Hb>=90g/L, WBC >=3.5×10^9/L,ANC>=1.5×10^9/L, PLT>=80×10^9/L; adequate renal function(Ccr<=ULN);adequate liver function(ALT,AST,AKP<=2.5*ULN,or <=5*ULN if liver metastases)
  • life expectancy >=12weeks;
  • no severe history disease of liver,heart,lung or kidney;
  • written informed consent form;

Exclusion Criteria:

  • Her-2 overexpression;
  • patients who has visceral endocrisis;
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01654185

Fudan University Cancer Hospital
Shanghai, China, 200032
Sponsors and Collaborators
Xichun Hu
Principal Investigator: Xichun Hu, MD,PhD Fudan University
  More Information

Responsible Party: Xichun Hu, Deputy director of department of medical oncology, Fudan University Identifier: NCT01654185     History of Changes
Other Study ID Numbers: Fudan BR2012-12
Study First Received: July 27, 2012
Last Updated: March 13, 2017

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Aromatase Inhibitors
Antineoplastic Agents
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 20, 2017